Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-12-12

FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for a fixed-dose combination of pioglitazone and glimepiride (Prasco Laboratories). The indication is for Type 2 dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pioglitazone and Glimepiride (pioglitazone and glimepiride)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)